Stocktoria
Invivyd, Inc. IVVD
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-08-06
Invivyd, Inc. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2021 |
|---|---|---|---|---|---|---|---|
| Revenue | $53.4M | $25.4M | $0 | — | — | — | — |
| R&D expense | $38.3M | $137.3M | $158.7M | $179.2M | $182.9M | — | — |
| SG&A expense | $66.9M | $63.4M | $49.1M | $47.0M | $36.5M | — | — |
| Operating income | -$55.6M | -$176.9M | -$212.8M | -$248.0M | -$226.9M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$52.5M | -$169.9M | -$198.6M | -$241.3M | -$226.8M | -$143.7M | -$83.4M |
| EPS (diluted) | $-0.30 | $-1.43 | $-1.81 | $-2.23 | $-5.32 | — | — |
| Operating cash flow | -$58.1M | -$170.5M | -$173.2M | -$220.0M | -$184.7M | — | — |
| Free cash flow | -$58.3M | -$170.6M | -$173.8M | -$221.7M | -$184.8M | — | — |
| Cash & equivalents | $226.7M | $69.3M | $200.6M | $92.1M | $542.2M | $478.3M | $392.5M |
| Inventory | — | $25.9M | $0 | — | — | — | — |
| Total assets | $276.9M | $129.5M | $229.2M | $383.2M | $620.1M | $686.3M | $398.0M |
| Total liabilities | $35.3M | $62.0M | $51.7M | $27.2M | $62.1M | $53.1M | $37.9M |
| Shareholders' equity | $241.5M | $67.5M | $177.5M | $356.0M | $558.0M | $633.2M | -$144.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2021 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +110.5% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.